Alternatives to AtaiBeckley

Develops long-acting implantable and injectable therapies for opioid addiction and chronic pain.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

A global leader in clinical pharmacology and bioanalytical sciences.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

Developing novel immunotherapies and diagnostics for cancer.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Developing gene editing therapies to lower cholesterol.

Biotechnology company developing immuno-neurology therapies for neurodegenerative diseases.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

AI-powered breast cancer detection and risk assessment solutions.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

H1 is a healthcare data platform that connects life sciences companies with healthcare professionals.

Developing ultrasound-mediated nonviral genetic medicines.

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Developing oral small molecule medicines for immunological and chronic diseases.

Pioneering vision restoration therapies for severe retinal degenerations.

A full-stack spatial biology company.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Immunotherapy company targeting oncology and autoimmune diseases.

Developing epigenetic reprogramming drugs for age restoration.

Developing first-in-class oral therapy for BK polyomavirus infections.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Developing novel male contraceptives.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Developing a new histotripsy therapeutic platform for cancer treatment.

Develops an endovascular solution for vasospasm treatment in aneurysmal subarachnoid hemorrhage.

Advancing targeted alpha therapies.

Global leader in enzymatic therapeutics for non-surgical tissue repair, replacing existing standards of care.

Develops and distributes bioreactor technology for stem cell cultivation.

Platform designed to cut cell and gene therapy production costs.

A biopharmaceutical company focused on drug discovery and development.

AI-enabled technology for cell biology research and biopharma development.

Elevating uterine health through innovative biomaterial therapies.

Develops multimodal hemoadsorption therapeutic devices for sepsis and septic shock.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.